deListed Australia
 
SEARCH LISTED OR DELISTED COMPANY
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY
SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

QUEENSLAND BAUXITE LIMITED (ASX.QBL)

ASX Announcements (courtesy of ASX)

201120122013201420152016201720182019

ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)
Former (or subsequent) names
CompanyFROMTO
CANN GLOBAL LIMITED25/01/2019
QUEENSLAND BAUXITE LIMITED23/02/201125/01/2019
AUSTRALIAN GOLD INVESTMENTS LIMITED23/02/2011
Shareholder links
Our website ranking of QBL: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Computershare Sydney
Level 3, 60 Carrington Street, Sydney NSW 2000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details
Address: 24 Birriga Rd Bellevue Hill NSW 2023
Tel:  02-9291-9000 Fax: 02-9291-9099

Date first listed: 14/01/2008

Sector: Materials
Industry Group: XMJ
Activities: Gold exploration at the Broad Dams Project in Kalgoorlie and the Pilbara Gold Project in the southwest Pilbara, both in Western Australia

name changed to Cann Global Limited

25/01/2019

The company has received the formal approval letter for its application for reinstatement to the official list of ASX Limited. The terms of the ASX waivers granted in connection with the approval are set out in the company's announcement.

14/01/2019

The company releases cover letter and supplementary prospectus

24/12/2018

The company issues cover note to supplementary prospectus and relisting update

21/12/2018

The company issues a seventh supplementary prospectus to be read in conjunction with the prospectus and other supplementary prospectus previously released.

14/12/2018

The company issues a sixth supplementary prospectus to be read in conjunction with the prospectus and other supplementary prospectus previously released.

07/12/2018

The company releases a fifth supplementary prospectus to be read in conjunction with the prospectus and other supplementary prospectus previously released.

28/11/2018

The company was successful in its Federal Court proceedings for validation orders in relation to secondary trading in a number of shares issued by the Company during the last 6 years. The orders obtained were that dealings in the relevant shares were not invalid by reason of the failure by those who have sold the securities to comply with section 707(3) and section 727(1) in Part 6D.2 of the Corporations Act and that the sellers be relieved from any civil liability in respect of the contravention of those provisions. The Company also obtained orders to cleanse any securities which were issued contrary to the requirements of Part 6D.2 requirements so that they are freely tradable.

27/11/2018

The company releases the results of its AGM.

27/11/2018

The company issues a fourth supplementary prospectus which is intended to be read with the prospectus dated 27 September 2018, the initial supplementary prospectus dated 17 October 2018, the second supplementary prospectus dated 31 October 2018 and third supplementary prospectus dated 7 November 2018.

14/11/2018

The company issues a third supplementary prospectus which is intended to be read with the prospectus dated 27 September 2018, the initial supplementary prospectus dated 17 October 2018 and the second supplementary prospectus dated 31 October 2018.

07/11/2018

The company lodges its Quarterly Activities and Cashflow Report.

31/10/2018

The company issues a supplementary prospectus that includes updated information on the original prospectus that was lodged with the ASIC on 27 September 2018 and the first supplementary prospectus lodged with the ASIC on 17th October 2018. The Company is very pleased and grateful for the overwhelming support of our shareholders in their support of the Offer, with the Company having received applications under the Capital Raising Offer exceeding the maximum subscription of $5,950,000.

31/10/2018

The company releases a notice of AGM. The meeting will be held at 2:00pm (AEDT) on Tuesday 27 November 2018 at Computershare Investor Services Pty Limited Level 4, 60 Carrington Street Sydney, NSW.

29/10/2018

Medcan Australia, has entered into a Strategic Collaboration and Supply Agreement Signed with an established Canadian Licensed Producer of Medical Cannabis. As a result of a relationship forged over the past two years, Medcan Australia has formalised a significant Collaboration Agreement with Bonify Holdings Corporation, a Canadian Licensed Producer of Medical Cannabis, for Medcan to provide medical cannabis products to Bonify for distribution in the bourgeoning Canadian market.

24/10/2018

The company lodges its Annual Report to shareholders.

23/10/2018

Medcan Australia has entered into a memorandum of understanding with top Israeli medicinal cannabis company Pharmocann. Pharmocann is recognised as being amongst the world's foremost and experienced cannabis growers, with their own proprietary products, intellectual property and expertise that will be of significant benefit to the Australian and global markets. This MOU follows on from Medcan securing its Medical Cannabis Manufacturing License and Export License from the Office of Drug Control.

19/10/2018

The company issues a supplementary prospectus with update information on the original prospectus that was lodged with the ASIC on 27 September 2018.

18/10/2018

Medcan Australia has secured a Medical Cannabis Manufacture Licence under the ODC. This licence will allow Medcan, subject to individual permit issue, the ability to manufacture its range of products.

09/10/2018

The company has corrected som minor typographical errors in the prospectus that was earlier lodged with the ASX announcements platform.

01/10/2018

The company issues a recompliance prospectus for an offer of up to 170,000,000 new Shares at an issue price of $0.035 per Share to raise up to $5,950,000, with a minimum subscription of $1,995,000 together with one (1) free attaching Option for every two (2) Shares subscribed for and issued. This Prospectus also contains the additional offers of Shares.

28/09/2018

The company releases the results of its meeting.

14/09/2018

The company releases a letter from the chairperson regarding a set of proposed resolutions and explanatory statements which will see the merger of Medical Cannabis Limited into the Company and the acquisition of MedCan Australia. All the Directors are in favour of all resolutions and believe that upon completion of the recompliance the Company will achieve being a leader in the world Cannabis market.

22/08/2018

The company has entered into a heads of agreement with Sebastian and Samuel Edwards (HHC) to acquire their Health Food Brands. Sebastian & Samuel Edwards are the owners and directors of Hemp Hulling Co (HHC), of which QBL's subsidiary Medical Cannabis Limited (MCL) owns 55%.

16/08/2018

The company releases a notice of general meeting, which states that the meeting will be held at 11.30 (EST) on 14 September 2018 at Computershare Investor Services Pty Limited Level 4, 60 Carrington Street Sydney, NSW.

16/08/2018

Following a scheduled ASX internal system change affecting the Market Announcements Platform, it has been necessary to re-apply the "˜Suspend' session state. This announcement serves to re-confirm the securities of this entity remain suspended.

06/08/2018

The company announces a ground-breaking discovery in medical cannabis research. Professor Meiri tells of his significant discovery as follows: "In the past year the laboratory for cannabinoid research at the Technion- The Technology Institute of Israel, initiated a research program funded by MCL. The overall objective of this study is to match effective cannabis extracts that regulate/modulate immune function, specifically, autoimmunity in MS, in order to optimize treatment for MS patients."

01/08/2018

The securities of Queensland Bauxite Limited will remain suspended from quotation pursuant to Listing Rule 17.3, following the announcement that the Company intends to amend the terms of the transaction requiring recompliance with Chapters 1 and 2 of the Listing Rules. The Company's securities will remain suspended until the Company has recompiled with Chapters 1 and 2 of the Listing Rules.

01/08/2018

Due to current market conditions, the intended capital raise at 8c is no longer an immediate practical option. As a result, the Board has decided to amend the raising price for the recompliance. The revised offer will be a discounted raising exclusively to shareholders of QBL. The directors intend to utilise their discretion to allocate the raising to shareholders in accordance with the size of their shareholding and the length of time the shareholder has held their shares. The offer will be open to all shareholders, and the directors will try to accommodate as many shareholders as possible pro rata to their shareholding. The exclusive offer will be for a minimum raising of $2M and an oversubscription up to a maximum raising of $6M, at 3.5c per share and one attaching 18 month option at 10c exercise price for every two shares subscribed for. The company has also come to an agreement with Medcan to extend the date for completion of the Medcan acquisition agreement to the 31st October 2018.

01/08/2018

The company lodges its Quarterly Activities and Cashflow Report.

01/08/2018

The company will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 1 August 2018, following failure to lodge the quarterly report for the quarter ended 30 June 2018 by the due date.

01/08/2018

The suspension of trading in the securities of Queensland Bauxite Limited will be lifted from the commencement of trading on Thursday, 21 June 2018, following the release by the Company of an announcement regarding a significant acquisition to which Listing Rule 11.1.3 applies.

20/06/2018

The company and its subsidiary, Medical Cannabis Limited, have entered into a legally binding heads of agreement to acquire a 100% interest in Medcan. Medcan has an ODC Medical Cannabis Production License to legally cultivate and produce high THC / CBD chemovars and cultivars to make medicinal Cannabis products in Australia. MCL now has access to an ODC medicinal cannabis production license which will enable value maximisation of MCL's established seed bank, unique cannabis genetics and medical cannabis distribution divisions. QBL has elected not to float MCL but to obtain approval from QBL's shareholders at a general meeting to purchase the remaining 45% of MCL and completely incorporate MCL into QBL for the benefit of all QBL shareholders.

20/06/2018

ASX has approved the company's announcement to be released. The company intends to release the announcement on 21 June 2018. QBL will recommence trading on the ASX following the release of the announcement.

18/06/2018

The company is in the closing stages of completing the approval process with the ASX of the transactions, and has now provided the ASX with all the information that had been requested by ASX to be included in the detailed announcement. The Company is now waiting for the formal final approval of the detailed announcement by the ASX, which, once released to the market, will enable the Company to resume trading on the ASX.

08/06/2018

The detailed information on the acquisitions is now being completed and is in the process of being forwarded today to the ASX. The ASX have indicated that they will require to further review and approve the documentation with the relevant departments within the ASX next week. The Company is expecting to be able to resume trading on the ASX once the ASX approves the release of the announcement.

01/06/2018

The company requests a further extension of the suspension of its securities to allow the directors of QBL and MCL to complete the first comprehensive draft announcement to the conditions recently given by the ASX, and to give time for ASX to approve the final version. This detailed process is now understood by the Company to be very close to completion and approval, and this is now expected to be finalised with the ASX on or before trading on Friday, the 1 st of June 2018.

25/05/2018

The company requests a further extension on its securities to complete the final comprehensive draft announcement. This is expected to be finalised on or before 25 May 2018.

17/05/2018

A further 7 day continuance of suspension is requested until finalisation of the release to the market of a material announcement regarding the significant and strategic acquisition deal entered into by QBL's subsidiary Medical Cannabis Limited. The release is expected to be finalised with the ASX by 17 May 2018.

09/05/2018

The company requests an extension of the voluntary suspension on its securities until finalisation of the release to the market of a material announcement regarding the significant and strategic acquisition deal currently being finalised by Medical Cannabis. The deal is expected to be finalised with the ASX today or prior to trading on 9 May 2018.

07/05/2018

The securities of Queensland Bauxite Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement.

04/05/2018

The suspension of trading in the securities of Queensland Bauxite Limited will be lifted from the commencement of trading on Tuesday, 9 January 2018, following the release by the Company of an announcement regarding a medical product joint venture deal signed by its subsidiary Medical Cannabis Limited.

08/01/2018

VitaCann has signed an exclusive joint venture agreement for a World First Pharmaceutical Grade Medial Cannabis Extended Release Pill with Canntab Therapeutics Limited of Toronto, Ontario, Canada.

08/01/2018

The securities of Queensland Bauxite Limited will be suspended from official quotation immediately, at the request of the Company pursuant to listing rule 17.2, pending the release of an announcement regarding a medical product joint venture deal signed by its subsidiary Medical Cannabis Limited.

08/01/2018

The suspension of trading in the securities of Queensland Bauxite Limited (the " Company") will be lifted before the commencement of trading tomorrow, Tuesday 30 December 2014, following receipt of announcements regarding the South Johnstone Bauxite Project and the Company's quarterly report for the period ended 30 September 2014. Security Code: QBL

30/12/2014

The JORC Compliant Indicated Mineral Resource estimate has been reviewed and completed by Independent Consultants. An updated Scoping Study has also been completed based solely on a higher confidence level JORC Compliant Indicated Mineral Resource. An Indicated mineral resource is a higher geological level of confidence by comparison to an Inferred mineral resource, which enables a greater level of confidence in projecting more accurate production and profitability in the pre-mining Scoping Study

24/12/2014

the Company is preparing a resource upgrade report to an Indicated Mineral Resource status under JORC 2012 which will give the basis to start project development at the South Johnstone Bauxite project

11/12/2014

At the Annual General Meeting, shareholders passed resolutions as detailed in the Notice of Meeting for the: ï‚· Adoption of the Remuneration Report ï‚· Re-election of Director "“ Sholom Feldman ï‚· Election of Director "“ Meyer Gutnick ï‚· Potential Share Placement Approval

26/11/2014

the directors of Queensland Bauxite Limited (ASX:QBL) would like to inform shareholders that more results from our recent expanded drilling programme in one of the higher grade areas of the South Johnstone Bauxite Project have been received that warrant inclusion in the current resource upgrade estimate

18/11/2014

The directors of QBL wish to inform shareholders and the market, that the process of preparing the report relating to the upgrading of the resource underpinning the scoping study is still ongoing

12/11/2014

The securities of Queensland Bauxite Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement. Security Code: QBL

04/11/2014

The suspension of trading in the securities of Queensland Bauxite Limited will be lifted immediately, following receipt of an announcement. Security Code: QBL

18/06/2014

The securities of Queensland Bauxite Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. Security Code: QBL

17/06/2014

The suspension of trading in the securities of Queensland Bauxite Limited will be lifted immediately, following receipt of an announcement responding to an ASX price and volume query. Security Code: QBL

03/06/2014

The securities of Queensland Bauxite Limited (the "Company") will be suspended from quotation immediately, by ASX pursuant to listing rule 17.3. Security Code: QBL

03/06/2014

name changed from Australian Gold Investments Limited

23/02/2011
View ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates
Post your comments here
Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    NAMETITLEDATE OF APPT
    Pnina FeldmanChairman12/04/2007
    Sholom FeldmanCEO09/11/2007
    Meyer GutnickNon Exec Director04/03/2014
    David AustinAlternate Director15/04/2008
    Sholom FeldmanCompany Secretary

    Date of first appointment, title may have changed.

    SPECIAL NOTE: During May 2024 we are working to remove duplications in the Company Secretary role.

    Directors & Executives (former)
    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Paul StephensonNon Exec Director07/10/200804/03/2014
    Russell WilliamsNon Exec Director18/04/201107/02/2014

    Date of first appointment, title may have changed.